XML 35 R10.htm IDEA: XBRL DOCUMENT
v3.25.3

Balance Sheet Accounts | 12 Months Ended
--- | ---
Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Accounts | BALANCE SHEET ACCOUNTSProperty, Plant and Equipment The following table summarizes the Company’s major classes of property, plant and equipment:
| September 30,
| 2025 |  | 2024
| (in thousands)
Land | $ | 2,996 |  |  | $ | 2,996 |
Buildings | 251,317 |  |  | 75,988 |
Research equipment | 62,758 |  |  | 65,353 |
Manufacturing equipment | 18,588 |  |  | — |
Furniture | 5,594 |  |  | 5,594 |
Computers and software | 1,064 |  |  | 981 |
Leasehold improvements | 104,425 |  |  | 104,410 |
Construction in progress | 15,942 |  |  | 188,731 |
| 462,684 |  |  | 444,053 |
Less: Accumulated depreciation and amortization | (80,169) |  |  | (58,021) |
Property, plant and equipment, net | $ | 382,515 |  |  | $ | 386,032 |
Depreciation and amortization expense for property, plant and equipment for the years ended September 30, 2025, 2024, and 2023 was $22.2 million, $16.9 million and $10.7 million, respectively. During the first quarter of fiscal 2025, the Company substantially completed the build out of its manufacturing facility in Verona, Wisconsin, leading to the reclassification of $162.7 million from construction in progress to buildings and $2.6 million from construction in progress to manufacturing equipment. The Company subsequently incurred and capitalized $10.6 million to buildings and $16.0 million to manufacturing equipment during the remainder of fiscal 2025. Furthermore, the Company began depreciating the newly completed manufacturing facility over a 39-year period and the manufacturing equipment over 7- or 10-year periods. During the first quarter of fiscal 2024, the Company completed the build out of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $71.8 million from construction in progress to buildings. The Company subsequently incurred and capitalized $4.2 million from construction in progress to buildings in fiscal 2024. Accrued Expenses Accrued expenses consisted of the following:
| September 30,
| 2025 |  | 2024
| (in thousands)
Accrued research and development expenses | $ | 30,330 |  |  | $ | 28,069 |
Accrued research and development expenses; co-development | 31,296 |  |  | 23,351 |
Accrued capital expenditures | 277 |  |  | 4,206 |
Accrued income taxes (benefits) | 20,799 |  |  | — |
Other | 7,717 |  |  | 7,391 |
Total accrued expenses | $ | 90,419 |  |  | $ | 63,017 |
As of September 30, 2025, the Company’s accrued research and development expenses was primarily attributable to ongoing clinical trial operations, preclinical animal studies, and associated toxicology assessments. In addition, accrued research and development expenses; co-development relates to the co-development and co-commercialization activities under the Takeda License Agreement (see Note 2).

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration